First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
← catalyst calendarNCT06644755 · readout in 834 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
150estimated
Sites
7
Countries
Belgium, France, Netherlands +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-14 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumors
- Sarcoma
Intervention
- Drug: DS-2243a
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of participants with Dose-Limiting Toxicities at each dose level of DS-2243a
measured Up to 18 months
Part 2: Number of participants with Treatment-Emergent Adverse Events
measured Up to 3 years
Part 2: Objective Response Rate
measured From day of first dose up to 3 years
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed